BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15251985)

  • 1. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.
    Novak AJ; Grote DM; Stenson M; Ziesmer SC; Witzig TE; Habermann TM; Harder B; Ristow KM; Bram RJ; Jelinek DF; Gross JA; Ansell SM
    Blood; 2004 Oct; 104(8):2247-53. PubMed ID: 15251985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
    Fu L; Lin-Lee YC; Pham LV; Tamayo A; Yoshimura L; Ford RJ
    Blood; 2006 Jun; 107(11):4540-8. PubMed ID: 16497967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.
    Briones J; Timmerman JM; Hilbert DM; Levy R
    Exp Hematol; 2002 Feb; 30(2):135-41. PubMed ID: 11823048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
    He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
    J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.
    Marsters SA; Yan M; Pitti RM; Haas PE; Dixit VM; Ashkenazi A
    Curr Biol; 2000 Jun; 10(13):785-8. PubMed ID: 10898980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
    Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
    Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
    Novak AJ; Darce JR; Arendt BK; Harder B; Henderson K; Kindsvogel W; Gross JA; Greipp PR; Jelinek DF
    Blood; 2004 Jan; 103(2):689-94. PubMed ID: 14512299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency.
    Yan M; Brady JR; Chan B; Lee WP; Hsu B; Harless S; Cancro M; Grewal IS; Dixit VM
    Curr Biol; 2001 Oct; 11(19):1547-52. PubMed ID: 11591325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
    Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
    Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.
    Novak AJ; Grote DM; Ziesmer SC; Kline MP; Manske MK; Slager S; Witzig TE; Shanafelt T; Call TG; Kay NE; Jelinek DF; Cerhan JR; Gross JA; Harder B; Dillon SR; Ansell SM
    J Clin Oncol; 2006 Feb; 24(6):983-7. PubMed ID: 16432079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
    Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
    Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of BLyS action in B cell immunity.
    Do RK; Chen-Kiang S
    Cytokine Growth Factor Rev; 2002 Feb; 13(1):19-25. PubMed ID: 11750877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody.
    Nakamura N; Hase H; Sakurai D; Yoshida S; Abe M; Tsukada N; Takizawa J; Aoki S; Kojima M; Nakamura S; Kobata T
    Virchows Arch; 2005 Jul; 447(1):53-60. PubMed ID: 16025281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors.
    Shen X; Wang M; Guo Y; Ju S
    Adv Clin Exp Med; 2016; 25(5):837-844. PubMed ID: 28028945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.
    Luster TA; Mukherjee I; Carrell JA; Cho YH; Gill J; Kelly L; Garcia A; Ward C; Oh L; Ullrich SJ; Migone TS; Humphreys R
    PLoS One; 2012; 7(10):e47361. PubMed ID: 23056634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.
    Ju S; Zhang D; Wang Y; Ni H; Kong X; Zhong R
    Clin Biochem; 2006 Dec; 39(12):1131-7. PubMed ID: 17069785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BLyS and APRIL expression in peripheral blood mononuclear cells of cryptococcal meningitis patients and their clinical significance.
    Xia R; Han Z; Zhou Y; Chen S; Chen B; Gu M; Deng A; Zhong R; Wen H
    Clin Biochem; 2010 Mar; 43(4-5):397-400. PubMed ID: 19909733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
    Shivakumar L; Ansell S
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of expression levels of BLyS and its receptors with multiple myeloma.
    Ju S; Wang Y; Ni H; Wang X; Jiang P; Kong X; Zhong R
    Clin Biochem; 2009 Mar; 42(4-5):387-99. PubMed ID: 19028483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology. Lymphocyte survival--ignorance is BLys.
    Laâbi Y; Strasser A
    Science; 2000 Aug; 289(5481):883-4. PubMed ID: 10960320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.